Literature DB >> 3910785

Sarcomas of the vagina and uterus: the Intergroup Rhabdomyosarcoma Study.

D M Hays, H Shimada, R B Raney, M Tefft, W Newton, W M Crist, W Lawrence, A Ragab, H M Maurer.   

Abstract

During a 12-year period (1972-1984), 43 patients with sarcomas of the female genital tract were admitted to the Intergroup Rhabdomyosarcoma Study (IRS), including 31 with primary tumors of the vagina; and 12 with tumors of the uterus, including the cervix. Thirty-four of these can be evaluated on the basis of periods of observation from 18 months to 12 years. Primary tumors of the uterus were a distinct group, distinguished from those arising in the vagina by patient age-range and probably by prognosis, as well as site. Patients with vaginal tumors, with a mean age of 1.8 years, responded to a multimodality approach employing combinations of chemotherapy (vincristine sulfate and actinomycin D, or the aforementioned two drugs with cyclophosphamide +/- doxorubicin hydrochloride), irradiation, and/or surgery, with only one tumor-related death, among 24 evaluable patients. In contrast, among the patients with primary uterine tumors, in which the mean age was greater than 14 years, four of ten evaluable patients died secondary to tumor relapse or progression.

Entities:  

Mesh:

Year:  1985        PMID: 3910785     DOI: 10.1016/s0022-3468(85)80032-4

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  10 in total

1.  Vaginal tumors in childhood: the experience of St. Jude Children's Research Hospital.

Authors:  Israel Fernandez-Pineda; Sheri L Spunt; Lalit Parida; Matthew J Krasin; Andrew M Davidoff; Bhaskar N Rao
Journal:  J Pediatr Surg       Date:  2011-11       Impact factor: 2.545

2.  Spindle cell rhabdomyosacoma of uterus: a case study.

Authors:  Dae Woon Kim; Jung Hwan Shin; Ho Jung Lee; Young Ok Hong; Jong Eun Joo; Eun Kyung Kim
Journal:  Korean J Pathol       Date:  2013-08-26

3.  Robotic radical hysterectomy and pelvic lymphadenectomy for uterine rhabdomyosarcoma.

Authors:  Floor J Backes; Leigh G Seamon; Jeffrey M Fowler
Journal:  J Robot Surg       Date:  2008-08-05

Review 4.  Embryonal rhabdomyosarcoma of the uterine cervix.

Authors:  Georgios V Koukourakis; Vassilios Kouloulias; Georgios Zacharias; Georgios Maravelis; Christos Papadimitriou; Kaliopi Platoni; Athanasios Gouliamos
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405

Review 5.  Management of stage I cervical sarcoma botryoides in childhood and adolescence.

Authors:  Susanne E M Gruessner; Charles O A Omwandho; Thomas Dreyer; Renate Blütters-Sawatzki; Alfred Reiter; Hans R Tinneberg; Rainer M Bohle
Journal:  Eur J Pediatr       Date:  2004-06-02       Impact factor: 3.183

6.  Pediatric radical abdominal trachelectomy for anaplastic embryonal rhabdomyosarcoma of the uterine cervix: an alternative to radical hysterectomy.

Authors:  Mark L Kayton; Leonard H Wexler; Sharyn N Lewin; Kay J Park; Michael P La Quaglia; Nadeem R Abu-Rustum
Journal:  J Pediatr Surg       Date:  2009-04       Impact factor: 2.545

7.  Conservative treatment followed by chemotherapy with doxorubicin and ifosfamide for cervical sarcoma botryoides in young females.

Authors:  G Zanetta; S M Rota; A Lissoni; S Chiari; G Bratina; C Mangioni
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

8.  Fertility-sparing surgery for the management of young women with embryonal rhabdomyosarcoma of the cervix: A case series.

Authors:  Geneviève Bouchard-Fortier; Raymond H Kim; Lisa Allen; Abha Gupta; Taymaa May
Journal:  Gynecol Oncol Rep       Date:  2016-08-26

9.  Rhabdomyosarcoma of the genital tract in an 18-month-old girl.

Authors:  Nourah ALSaleh; Hadeel ALwadie; Abdulrahim Gari
Journal:  J Surg Case Rep       Date:  2017-04-27

10.  Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes.

Authors:  Ashley Albert; Anna Lee; Robert Allbright; Srinivasan Vijayakumar
Journal:  J Gynecol Oncol       Date:  2019-10-23       Impact factor: 4.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.